贝伐单抗、帕妥珠单抗和长效奥曲肽联合治疗晚期神经内分泌癌患者的II期研究
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
作者信息
Bendell Johanna C, Zakari Ahmed, Lang Evan, Waterhouse David, Flora Douglas, Alguire Kathryn, McCleod Michael, Peacock Nancy, Ruehlman Peter, Lane Cassie M, Earwood Chris, Shih Kent
机构信息
a Sarah Cannon Research Institute , Nashville , TN , USA.
b Tennessee Oncology, PLLC , Nashville , TN , USA.
出版信息
Cancer Invest. 2016 May 27;34(5):213-9. doi: 10.3109/07357907.2016.1174257. Epub 2016 Apr 29.
PURPOSE
To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.
METHODS
Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.
RESULTS
Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively.
DISCUSSION
Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.
目的
评估贝伐单抗、帕妥珠单抗和长效奥曲肽治疗晚期神经内分泌肿瘤的疗效和安全性。
方法
患者接受贝伐单抗15mg/kg和帕妥珠单抗420mg静脉注射，每21天一次，同时接受长效奥曲肽30mg肌肉注射，每28天一次。
结果
43例患者的毒性反应包括腹泻（63%）、疲劳（63%）、高血压（44%）和恶心（44%）。出现了可逆性3级高血压（26%）和左心室射血分数下降（9%）。43例患者中有7例获得客观缓解（典型类癌5例，胰腺神经内分泌肿瘤2例）。中位无进展生存期和总生存期分别为6.5个月和26.4个月。
讨论
贝伐单抗、帕妥珠单抗和长效奥曲肽耐受性良好，客观缓解率为16%。在高分化类癌肿瘤中的结果发人深省。
Zotero 插件